Proprietary Platforms
ReiCell-AAV
A Scalable HEK293 Line for AAV Vector Manufacturing
ReiCell-AAV is ReiThera’s proprietary clonal HEK293 suspension cell line, developed for high-efficiency, large-scale AAV production. Engineered to meet the highest standards of safety, productivity, and scalability, it provides a powerful platform for gene therapy developers.
1
Built for Safety and Regulatory Confidence
- Originates from the well-characterized p6 HEK293 lineage (frozen in 1973)
- No SV40 large T antigen, eliminating oncogenic safety concerns
- Ideal for clinical development and regulatory approval
2
Scalable Growth and Transfection
- Grows in chemically defined, high-density suspension cultures
- Supports efficient transfection across AAV serotypes (e.g., AAV2, AAV8)
- Maintains high productivity across a broad range of genes of interest
3
Proven Purity and Performance
- Achieves high VG titers with excellent batch consistency
- Validated purification process ensures:
- High yield
- Significant reduction in host cell protein (HCP) and DNA (HCDNA)
- Regulatory-compliant product purity
4
A Trusted Platform for Gene Therapy Developers
From early research to commercial production, ReiCell-AAV supports:
- Preclinical & IND-enabling studies
- Clinical trials
- Commercial-scale manufacturing
Its versatility, reproducibility, and regulatory-ready profile make it a compelling choice for AAV-based gene therapies.
Available for Licensing
ReiCell-AAV is now available for licensing. Partner with ReiThera to advance your gene therapy pipeline with a scalable, high-performance AAV manufacturing solution.
